Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJHN0A)

• Drug Name: Icosapent Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hyperglyceridemia	5C80.1	Approved	[1]
Thrombin deficiency	3B14.Z	Approved	[2]
Hypertriglyceridemia	5C80.1	Phase 3	[3]

• Therapeutic Class: Dietary supplement
• Cross-matching ID:
  PubChem CID: 446284
  ChEBI ID: CHEBI:28364
  CAS Number: CAS 10417-94-4
  TTD Drug ID: DMJHN0A

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase (COX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[6]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[7]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[8]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[9]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[10]
Oxaprozin	DM9UB0P	Osteoarthritis	FA00-FA05	Approved	[11]
Aceclofenac	DMZDF0B	Inflammation	1A00-CA43.1	Approved	[12]
Lornoxicam	DMYZFXN	Migraine	8A80	Approved	[13]
Morniflumate	DM9UTDE	Otitis media	AA80-AB0Z	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN; PGH2_HUMAN	Binder	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7441).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT01047683) Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels 500 and 2000 mg/dL. U.S. National Institutes of Health.
• [4] Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86.
• [5] Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
• [6] Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
• [7] Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
• [8] Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
• [9] Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
• [10] Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
• [11] The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
• [12] Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
• [13] The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
• [14] Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.